A breakthrough in medical injections

Group Copy

ApiJect has completely reimagined how to make and fill a new kind of prefilled injector that can deliver medicines and vaccines with enormous speed, scale, and efficiency.

Girl getting vaccine
https://apiject.com/wp-content/uploads/2020/09/ApiJect-Prefilled-Injector-275px-by-180px.jpg
https://apiject.com/wp-content/uploads/2020/09/woman-in-doctor-office-315-x-400px.jpg
https://apiject.com/wp-content/uploads/2020/09/Children.jpg
Introducing the

ApiJect Prefilled Injector

ApiJect™ combines the globally trusted technology of Blow-Fill-Seal (BFS) aseptic plastic drug packaging with pen needle-style hubs*.

BFS soft plastic containers package billions of doses a year.

Snapped together, these 3 components form the ApiJect Prefilled Injector.

A sterile Needle Hub* is affixed to the top of the container by the nurse, using a connector.

*This device is not cleared by the FDA for distribution in the United States.

The ApiJect Prefilled Injector provides

Reliable aseptic filling

Single-dose safety

Ready-to-use

That’s why the U.S. Government is working with ApiJect to fill and finish COVID-19 vaccine for hundreds of millions of Americans.

We’re proud to partner with the U.S. Department of Health and Human Services and the U.S. Department of Defense to strengthen America’s medical supply chain on U.S. soil.

Revolutionizing injections, wherever they happen.

Aseptically filled, single-dose injectors that can be quickly scaled to enormous volumes will improve market coverage, patient safety, and outcomes for nearly all injectable drugs – in the U.S. and across the world.

Doctor in safety shield and mask

ApiJect Prefilled Injectors are Ideal for Pandemic Response

In a national bio-emergency such as a pandemic, governments need to be able to package enough medicines or vaccines for their population on short notice. This "surge capacity" can be extremely difficult for traditional drug packaging supply chains to achieve.

ApiJect Prefilled Injectors are ideal for this challenge. A single BFS manufacturing line can reliably fill 15 million doses a month in ready-to-use single-dose presentations. That is why ApiJect is working with the U.S. Government on COVID-19 response.

Pharmacists in stock room

Entering and Expanding Markets for Most Injectable Drugs

For decades, BFS has been used as primary packaging for a wide range of large and small molecules, as well as vaccines. ApiJect Prefilled Injectors unlock the reliable quality, scale, and manufacturing cost advantages of BFS for the injectables market.

Our products can open new markets for branded and generic injectable pharmaceuticals, as well as grow market share for more mature sectors. And, BFS efficiency gives pharmaceutical companies easy flexibility in scaling their operations.

Doctor with family

Finally, a Single-Dose Format that Can Compete

For injectables in low- and middle-income countries, multi-dose vials are widely preferred for their low manufacturing cost. But multi-dose vials have significant safety and usage drawbacks. The BFS Prefilled Syringe changes this equation. With a projected total cost per delivered dose that can compete with multi-dose vials and syringes, our injector enables pharmaceutical companies to give consumers everywhere the safety and convenience of a single-dose, ready-to-use presentation.

doctor injecting girl

The Potential to Unlock Access for Everyone

A single Rommelag® bp460 BFS machine can aseptically package 15 million doses a month. When combined with ApiJect’s Needle Hubs, these BFS containers become prefilled injectors, ready to use with vaccine, and scalable in very large quantities. 

 What’s more, as a single-dose presentation, the injector improves patient safety and healthcare convenience without increasing the total cost per delivered dose above that of WHO-approved multi-dose formats. Put together, it’s easy to see why ApiJect believes BFS prefilled, single-dose injectors are the key to improving access everywhere.

Blow-Fill-Seal is a trusted technology for aseptically fill-finishing drugs.

BFS is a globally-trusted, 50+ year-old packaging technology that fills and finishes tens of billions of inhalation, ophthalmics and injectable products including biologics, oral vaccines, and other drugs. In 2004, FDA guidance deemed BFS a proven advanced aseptic packaging process.

Biologics and vaccines that have been successfully filled (and several commercialized) in BFS primary packaging include Pulmozyme by Genentech, RSV vaccine by Novartis, and rotavirus vaccine by GlaxoSmithKline.

A non-stop 3-second process

BFS is a highly efficient, low-human-intervention drug packaging process. Every three seconds, a high-end BFS machine can reliably make and aseptically fill up to 25 medical-grade LDPE containers (that’s up to 200 million units a year).

01 Extruding

BFS machine pours molten plastic into tube shape (“parison”) inside Class A clean space.

02 Blowing

Airstream blows parison open. Bottom mold closes to create 2-chamber shape.

03 Filling

Rod inserted to fill parison with precise dose of liquid vaccine or medicine.

04 Sealing

Upper mold closes, sealing the top of container.

Rapid USA manufacturing
A Global Network for Manufacturing BFS Prefilled Injectors

ApiJect believes any organization should be able put its drug products in BFS prefilled, single-dose injectors. That is why ApiJect, in addition to establishing its own BFS facilities, is working with pharmaceutical companies and contract manufacturers to set up BFS manufacturing lines within their own facilities.

ApiJect’s first company-owned facility in North Carolina, USA will be able to fill and finish 2-3 billion injectors every year for our pharma partners, with nearly every line BSL-2 compliant and protectively isolated

The latest ApiJect news

09.14.2020

ApiJect is excited to announce Raj Asarpota as its new Chief Financial Officer

Rajesh (Raj) Asarpota , an accomplished Executive VP and CFO at multiple pharmaceutical and life science companies, has joined ApiJect as its new CFO.

07.23.2020

ApiJect announces its new CEO for both ApiJect Systems America and RAPID USA.

Leading pharmaceutical executive, Franco Negron, is appointed Chief Executive Officer of ApiJect Systems America and its subsidiary RAPID USA.

07.01.2020

ApiJect appears in the Republican’s House Energy & Commerce Committee white paper on Covid-19 vaccines and therapeutics.

The Republican staff on the U.S House of Representatives Energy and Commerce Committee included ApiJect in its report on America’s response to COVID-19.

Get in touch to explore opportunities.

To learn more about how the ApiJect Prefilled Injector can serve your company’s drug products and open new market opportunities, contact our team.